An Open-Label, Multi-center Protocol to Observe the Effects of Pegylated Interferon Alfa-2a (PEGASYS (R)) as Monotherapy in Patients with Chronic Hepatitis B who have Participated in Previous Roche or Roche Partner Protocols.

Trial Profile

An Open-Label, Multi-center Protocol to Observe the Effects of Pegylated Interferon Alfa-2a (PEGASYS (R)) as Monotherapy in Patients with Chronic Hepatitis B who have Participated in Previous Roche or Roche Partner Protocols.

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Mar 2014

At a glance

  • Drugs Peginterferon alfa-2a (Primary)
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 03 Mar 2014 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov record.
    • 06 Jul 2012 Actual patient number changed from 21 to 29 according to ClinicalTrials.gov.
    • 21 May 2012 Actual patient number is 24 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top